RxDoctor Payments Data

Bridget Sundell, MD

Ophthalmology · Virginia, MNNPI 1871691295

Payments from drug & device makers

$1,390in general payments, 2019–2025

Across 22 payments — averaging $63.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Rxsight Inc$1K
  • AbbVie$54
  • Biotissue Holdings Inc.$49
  • Novartis$35
  • The Cameron-ehlen Group, Inc.$29
  • Beaver-visitec International, Inc.$28
  • plus $91 from 5 others

What the payments were for

  • Consulting fees$1,00072%
  • Speaking & faculty fees$463%
  • Food & beverage$34425%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,390 in reported general payments places this provider in the 70th percentile of 330 ophthalmology providers in Minnesota.

See all ophthalmology providers in Minnesota

Medicare billing

Part B allowed, 2024
$170,877
Medicare patients
250
Services billed
1,216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj14$457,711
XiidraLifitegrast53$58,577
RestasisCyclosporine20$16,316
IlevroNepafenac40$15,350
Difluprednate42$4,909
Prednisolone Acetate87$4,786
Bromfenac Sodium40$3,976
MoxifloxacinMoxifloxacin Hcl85$2,877
Latanoprost97$1,497
Timolol Maleate38$572
ErythromycinErythromycin Base40$410
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat14$262

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$54$16,31620 claims
NovartisIlevro$35$15,35040 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 330 ophthalmology providers in Minnesota.

Other ophthalmology in Virginia

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →